Hodinový prehľad - Zdravotnícke a vedecké zaujímavosti

Súhrn: The agency had previously declined to approve the treatment twice, citing concerns about the single-arm IGNYTE trial and the lack of a control group Approval was based on the single-arm IGNYTE trial in 140 patients with stage IIIB, IIIC, or IV unresectable advanced melanoma whose disease progressed after at least 8 weeks of PD-1 blockade The FDA has granted accelerated approval to vusolimogene oderparepvec (Tudriqev, Replimune) in combination with nivolumab for adults with unresectable advanced cutaneous melanoma after progression on an anti-PD-1-based regimen.

Súhrn: METHODOLOGY - Researchers conducted a randomized double-blind, parallel-group trial over 24 weeks in Auckland, New Zealand, enrolling 150 adults aged 18-45 years with a BMI of 25-35 kg/m² - Participants attended monthly 1-hour group seminars providing general diet and exercise advice, including recommendations for protein at every meal, limiting unhealthy snacks, eating nutrient-dense foods, and exercising daily TOPLINE Adults with overweight or obesity who received a bitter hop extract (BHE) alongside monthly lifestyle advice lost more than 4% of their body weight and nearly 5 kg of fat mass over 24 weeks.

Súhrn: METHODOLOGY - Researchers conducted a post hoc analysis of baseline 18F-FDG PET-CT scans from the LYSA cohort to assess whether radiomic features predicted survival in patients with newly diagnosed primary mediastinal B-cell lymphoma - They included 180 treatment-naive patients (median age, 35 - Researchers extracted 12 three-dimensional PET features and selected three nonredundant ones for prognosis: TMTV (overall tumor burden), Dmax (reflecting disease spread), and medPCD (reflecting lesion compactness/massiveness).